Protective Effect of Pediococcus pentosaceus LI05 Against Clostridium difficile Infection in a Mouse Model

Abstract

Clostridium difficile infection (CDI) is a major cause of infectious diarrhea among hospitalized patients. Probiotics could be instrumental in restoring the intestinal dysbiosis caused by CDI. Here, we examined the protective effect of Pediococcus pentosaceus LI05 in a mouse CDI model. C57BL/6 mice were administrated P. pentosaceus LI05 (LI05 group) or sterile anaerobic PBS (CDI group) everyday for 14 days. Mice were exposed to antibiotics cocktail for 5 days; then challenged with C. difficile strain VPI10463. Mice were monitored daily for survival and weight loss. Colonic tissue and serum samples were assessed for intestinal histopathology, intestinal barrier function and systemic inflammation. The oral administration of P. pentosaceus LI05 improved the survival rate and alleviated the histopathological impact of C. difficile. Compared to the CDI group, the levels of inflammatory mediators in the colon as well as inflammatory cytokines and chemokines in serum were substantially attenuated in the LI05 group. P. pentosaceus LI05 alleviated the CDI-induced of disruption of ZO-1, occludin and claudin-1. Additionally, fecal microbiome analysis showed an enrichment in the abundance of the Porphyromonadaceae and Rikenellaceae, while, the relative abundance of Enterobacteriaceae were decreased. Our results demonstrated that the preventive effect of P. pentosaceus LI05 against CDI was mediated via improving tight junction proteins and down-regulating the inflammatory response. Therefore, P. pentosaceus LI05 could be a promising probiotic in CDI.

Pediococcus pentosaceus LI05 alleviates DSS‐induced colitis by modulating immunological profiles, the gut microbiota and short‐chain fatty acid levels in a mouse model

“…Gut microbes, which are relevant to host immunity and metabolism, are key factors contributing to IBD pathogenesis and development (Tamboli et al , 2004; Sartor, 2008; Marion‐Letellier et al , 2016). According to multiple studies, P. pentosaceus LI05 exerts an important effect on protecting the host intestine by regulating the gut microbiome, thereby strengthening the gut barrier and modulating the mucosal immunity, as well as host metabolism (Bengmark et al , 2011; Zhao et al , 2012; Lv et al , 2014b; Shi et al , 2017; Xu et al , 2018). Therefore, our study aimed to evaluate alterations in the gut microbiota, immune responses and metabolites (SCFA production) in a mouse model of DSS‐induced colitis after treatment with P. pentosaceus LI05.…”

“…In addition, several species of P. pentosaceus have been reported to alleviate encephalopathy, acute liver failure, obesity and fatty liver (Bengmark et al , 2011; Zhao et al , 2012; Shi et al , 2017). Our newly isolated probiotic P. pentosaceus LI05 has been shown to protect the host mucosa by strengthening the epithelial barrier function and regulating the host immunity and gut microbiota in mouse models of Clostridium difficile infection and CCl4‐induced cirrhosis (Shi et al , 2017; Xu et al , 2018). Based on these findings, P. pentosaceus LI05 may exert a beneficial and effect on preventing intestinal inflammation.…”

New strain of Pediococcus pentosaceus alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism

“…P. pentosaceus CGMCC 7049 is a newly isolated strain of bacteria that has been shown to be acid-tolerant and resistant to bile salts, with a high tolerance to 5% ethanol[ 14 ]. As shown in our previous studies, the administration of P. pentosaceus effectively inhibits pathogenic bacteria, such as Staphylococcus aureus and Clostridium difficile [ 14 , 15 ]. The relative abundance of Pediococcus is also significantly reduced in patients with ALD and animal models involving ethanol feeding[ 9 , 16 ].…”

Antibacterial Activity of Bifidobacterium breve Against Clostridioides difficile

“…Previous studies have indicated that some probiotics, such as Lactobacillus helveticus, Lactobacillus fermentum, Streptococcus thermophilus, Bifidobacterium longum , and Pediococcus pentosaceus inhibited C. difficile in vitro and in vivo . The antibacterial effect of these strains against C. difficile was mainly reflected in the inhibition of growth, suppression of sporulation, and degradation of toxin (Golic et al, 2017; Wei et al, 2018; Xu et al, 2018). However, few of investigation have focused on changes at the cellular level of C. difficile .…”